Skip to main content
Premium Trial:

Request an Annual Quote

HiberGene Receives CE Mark for Group B Strep Test

NEW YORK (GenomeWeb) – Irish molecular diagnostics firm HiberGene announced today that it has received CE marking for its HG Group B Streptococcus (GBS) test for the detection of strep infection in pregnant women using rectovaginal swabs.

The assay uses loop-mediated isothermal amplification to detect Streptococcus agalactiae infection — a common cause of neonatal meningitis that can also lead to septicemia and pneumonia — in under an hour. The test was cleared in Europe this summer for use with cerebrospinal fluid and whole blood from newborns, and enriched broth from pregnant women.

All of HiberGene's assays are designed to run on the company's HG Swift instrument, including its CE marked bacterial meningitis test.

"The ability to test for GBS in pregnant women with a simple swab will significantly improve patient care by returning a rapid test result," HiberGene CEO Brendan Farrell said in a statement. "This will mean that intrapartum testing can be a reality and will enable healthcare professionals to tailor a care plan to ensure correct treatment during labor."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.